A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
about
c-Met as a Target for Personalized TherapyOckham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerA human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinomaThe potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cellsA randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapyEmerging Therapeutic Targets for Male Germ Cell Tumors.Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.Current Management of Refractory Germ Cell Tumors and Future Directions.Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.Investigational targeted therapies for the treatment of testicular germ cell tumors.Promising new strategies for hepatocellular carcinoma.Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases.Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
P2860
Q26775483-AAFD2B3F-F949-44B0-AAAF-3A83B9916B1BQ28067777-31911CBF-F793-42CB-B1CD-7646D478E43DQ28487973-2CB17AE0-0510-4010-BF48-E3255BD277FBQ33769429-F9B89906-26A4-4133-9842-B3609FBABE27Q33823715-87F148D0-3E73-422B-A0AE-DE37A9B99B89Q37352435-43F20C75-0BEE-4E22-80F1-505179CD984AQ38602699-093BBCCA-EA83-44B8-873D-4BDB8E77B9D7Q38656908-8CB22EA7-0D16-4932-B537-B57EB355584BQ38702212-E2A663E0-D15F-44AF-BD69-CF9D873A1AF2Q38755132-3C9B5E18-C718-4D31-9990-9AF26566AD80Q38782345-B47C4B51-55C8-4722-B1BA-ADBFCC8B003CQ38861307-8ECB8A4C-9A93-4F26-8DC7-492F230A2B75Q38936589-8A1D706E-6203-4DA4-8AA2-4A92B8C631CBQ39604398-691CE2ED-F5BC-46E2-A83A-17FF9670B864Q40255155-8E481FFD-D52D-4FEF-AFDF-111258A54DB2Q48150809-8E86D24A-6BCF-4E3B-A138-8288892B759DQ50985091-6D48C68E-2474-4F3B-91CF-3466A11E437DQ51031755-ABF0667B-2083-405A-ABD7-C8FB2BC07A5B
P2860
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase 2 multicenter study of ...... r refractory germ cell tumors.
@ast
A phase 2 multicenter study of ...... r refractory germ cell tumors.
@en
type
label
A phase 2 multicenter study of ...... r refractory germ cell tumors.
@ast
A phase 2 multicenter study of ...... r refractory germ cell tumors.
@en
prefLabel
A phase 2 multicenter study of ...... r refractory germ cell tumors.
@ast
A phase 2 multicenter study of ...... r refractory germ cell tumors.
@en
P2093
P2860
P50
P1476
A phase 2 multicenter study of ...... or refractory germ cell tumors
@en
P2093
Abdel-Baset Halim
Aude Fléchon
David J Vaughn
Hamim Zahir
Johnathan K Joffe
Julio Hajdenberg
Lawrence H Einhorn
Yohann Loriot
P2860
P2888
P304
P356
10.1007/S10637-013-9934-Y
P577
2013-02-17T00:00:00Z
P5875
P6179
1033162552